Business Description
Chi Sheng Pharma & Biotech Co Ltd
NAICS : 339112
SIC : 3841
ISIN : TW0004111000
Description
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.45 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | 1.71 | |||||
| Interest Coverage | 35.36 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.34 | |||||
| Beneish M-Score | -2.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.7 | |||||
| 3-Year EBITDA Growth Rate | 9.5 | |||||
| 3-Year EPS without NRI Growth Rate | 35.1 | |||||
| 3-Year FCF Growth Rate | -4.8 | |||||
| 3-Year Book Growth Rate | 4.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.84 | |||||
| 9-Day RSI | 60.93 | |||||
| 14-Day RSI | 60.05 | |||||
| 6-1 Month Momentum % | -12.34 | |||||
| 12-1 Month Momentum % | 1.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 0.83 | |||||
| Days Inventory | 58.69 | |||||
| Days Sales Outstanding | 115.2 | |||||
| Days Payable | 42.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.66 | |||||
| Dividend Payout Ratio | 0.9 | |||||
| 3-Year Dividend Growth Rate | 18.6 | |||||
| Forward Dividend Yield % | 3.66 | |||||
| 5-Year Yield-on-Cost % | 5.06 | |||||
| Shareholder Yield % | 3.46 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.52 | |||||
| Operating Margin % | 6.42 | |||||
| Net Margin % | 7.66 | |||||
| FCF Margin % | 9.41 | |||||
| ROE % | 5.23 | |||||
| ROA % | 3.64 | |||||
| ROIC % | 3.25 | |||||
| ROC (Joel Greenblatt) % | 8.52 | |||||
| ROCE % | 6.1 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.45 | |||||
| PE Ratio without NRI | 25.45 | |||||
| Shiller PE Ratio | 17.69 | |||||
| Price-to-Owner-Earnings | 49.64 | |||||
| PEG Ratio | 3.07 | |||||
| PS Ratio | 1.95 | |||||
| PB Ratio | 1.31 | |||||
| Price-to-Tangible-Book | 1.32 | |||||
| Price-to-Free-Cash-Flow | 20.6 | |||||
| Price-to-Operating-Cash-Flow | 11.02 | |||||
| EV-to-EBIT | 18.75 | |||||
| EV-to-EBITDA | 11.67 | |||||
| EV-to-Revenue | 1.82 | |||||
| EV-to-FCF | 18.92 | |||||
| Price-to-Projected-FCF | 1.12 | |||||
| Price-to-DCF (Earnings Based) | 2.21 | |||||
| Price-to-DCF (FCF Based) | 1.79 | |||||
| Price-to-Median-PS-Value | 1.39 | |||||
| Price-to-Graham-Number | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 6.29 | |||||
| Earnings Yield (Greenblatt) % | 5.33 | |||||
| FCF Yield % | 4.83 | |||||
| Forward Rate of Return (Yacktman) % | 2.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chi Sheng Pharma & Biotech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 833.972 | ||
| EPS (TTM) (NT$) | 1.11 | ||
| Beta | 0.09 | ||
| Volatility % | 21.91 | ||
| 14-Day RSI | 60.05 | ||
| 14-Day ATR (NT$) | 0.562257 | ||
| 20-Day SMA (NT$) | 27.815 | ||
| 12-1 Month Momentum % | 1.12 | ||
| 52-Week Range (NT$) | 24.55 - 34.9 | ||
| Shares Outstanding (Mil) | 56.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chi Sheng Pharma & Biotech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chi Sheng Pharma & Biotech Co Ltd Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chi Sheng Pharma & Biotech Co Ltd Frequently Asked Questions
What is Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111)'s stock price today?
The current price of ROCO:4111 is NT$28.25. The 52 week high of ROCO:4111 is NT$34.90 and 52 week low is NT$24.55.
When is next earnings date of Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111)?
The next earnings date of Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111) is .
Does Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111) pay dividends? If so, how much?
The Dividend Yield %  of Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111) is 3.66% (As of Today), Highest Dividend Payout Ratio of Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111) was 1.08. The lowest was 0.21. And the median was 0.5. The  Forward Dividend Yield % of Chi Sheng Pharma & Biotech Co Ltd(ROCO:4111) is 3.66%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers